ImmunityBio Amends Convertible Note, Allowing Insider to Partially Convert $505M Debt to Equity

summarizeSummary

ImmunityBio, Inc. amended a $505 million convertible promissory note, granting Nant Capital, an affiliated entity, the flexibility to convert any portion of the outstanding principal into common stock at its discretion.

check_boxKey Events · Financing and Capital Events · IBRX

• Convertible Note Amendment

  ImmunityBio, Inc. entered into a letter amendment on January 23, 2026, to a $505 million convertible promissory note with Nant Capital, LLC, an entity affiliated with the Executive Chairman.

• New Partial Conversion Option

  The amendment now allows Nant Capital to convert any portion of the outstanding principal amount of the note into common stock at any time prior to the maturity date. Previously, the note did not provide for partial conversion.

• Potential for Significant Dilution

  This change grants a major affiliated holder increased flexibility to convert a substantial debt into equity, creating a potential overhang and future dilution for existing shareholders.

auto_awesomeAnalysis · IBRX · Life Sciences

This amendment to the convertible promissory note held by Nant Capital, an entity affiliated with the Executive Chairman, introduces significant potential for future dilution. By allowing partial conversion of the $505 million principal amount into common stock at any time, it creates an overhang on the stock. While not an immediate conversion, the increased flexibility for a major insider to convert a substantial debt into equity at their discretion could impact shareholder value. Investors should monitor any subsequent conversion notices from Nant Capital.